‹ ›
MYP_030041
← PREVIOUS NEXT → BACK
Basic Information
IN-1
Anticancer
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral replication inhibition
Enzyme modulation ▸ Enzyme inhibition ▸ Integrase inhibition
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
20 amino acids
C110H180N30O26S
Standard
Sequence
WQCLTLTHRGFVLLTITVLR
Physicochemical Analysis
2370.86 Da
10.35
1.84
1.57
0.0919
0.87
0.43
0.26
20.75
146.00
0.1000
5500.00
5500.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
908.50
-4.99
35.0
30.0
75.0
167.0
4.0
20.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0242238 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1:inhibition of integrase catalytic activity
77 %
Inhibition
PaperPubMed PMID: 18201721; PubMed PMID: 19850483 PMID18201721;19850483 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/18201721/
RECORD: Rec_0296993 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Replication inhibition
inhibition of strand transfer catalyzed by integrase
12 μM
IC50
Mammalian: 2.8 h; Yeast: 3 min; E. coli: 2 min
PaperCorrelation between shiftide activity and HIV-1 integrase inhibition by a peptide selected from a combinatorial library. | Armon-Omer A, Levin A, Hayouka Z, Butz K, Hoppe-Seyler F, Loya S, Hizi A, Friedler A, Loyter A. | J Mol Biol. 2008 Feb 29;376(4):971-82. | DOI:10.1016/j.jmb.2007.11.095 | PMID:18201721 PMID18201721 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/18201721/
RECORD: Rec_0348125 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
inhibition of intergration
63 %
Inhibition
PaperPubMed PMID: 18201721; PubMed PMID: 19850483 PMID18201721;19850483 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/18201721/
RECORD: Rec_0363910 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral Cytotoxic
PaperPubMed PMID: 18201721; PubMed PMID: 19850483 PMID18201721;19850483 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/18201721/
RECORD: Rec_0418229 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Replication inhibition
inhibition of virus replication in TZM-bl cells
62.5 μM
% inhibition
Mammalian: 2.8 h; Yeast: 3 min; E. coli: 2 min
PaperPeptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds. | Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A. | Bioorg Med Chem. 2009 Nov 15;17(22):7635-42. | DOI:10.1016/j.bmc.2009.09.053 | PMID:19850483 PMID19850483 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19850483/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records on this page · Page 3 of 4